Pyxis Oncology Inc. is a preclinical oncology company. It focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers. The company's product pipeline includes antibody drug conjugate and monoclonal antibody. Pyxis Oncology Inc. is based in CAMBRIDGE, Mass.
| Revenue (Most Recent Fiscal Year) | $16.15M |
| Net Income (Most Recent Fiscal Year) | $-77.33M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 0.94 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -3481.10% |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -68.56% |
| Return on Assets (Trailing 12 Months) | -52.14% |
| Current Ratio (Most Recent Fiscal Quarter) | 5.65 |
| Quick Ratio (Most Recent Fiscal Quarter) | 5.65 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $1.41 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.30 |
| Earnings per Share (Most Recent Fiscal Year) | $-1.04 |
| Diluted Earnings per Share (Trailing 12 Months) | $-1.60 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 62.02M |
| Free Float | 55.44M |
| Market Capitalization | $82.48M |
| Average Volume (Last 20 Days) | 0.47M |
| Beta (Past 60 Months) | 1.13 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 10.60% |
| Percentage Held By Institutions (Latest 13F Reports) | 39.09% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |